Franz Thomas Walt
Franz Thomas Walt (*1959, Switzerland) holds an MBA of City University, Bellevue, Washington and completed executive programs at Columbia University, IMD, Switzerland, London Business School and INSEAD, France.
Following his studies, Mr. Walt spent over 30 years in leadership roles at two of the world’s largest healthcare companies, Siemens Healthineers and Roche. Between 1989 and 2011 he held various positions of increasing responsibility in pharma and diagnostics, which includes CEO, Managing Director and President roles, in various geographic regions for Roche Diagnostics. Most recently he served eight years as a member of the Roche Diagnostics Executive Committee (DiaEC). After Roche, he worked for Siemens Healthineers AG between 2012 and 2017, most recently as President of Laboratory Diagnostics. Since 2018, he has been Chief Executive Officer of NASDAQ-listed Quotient Ltd. Eysins, Switzerland.
Mr. Walt has been a member of the Supervisory Board of Epigenomics AG since May 2019. The current term ends in 2021. He is an independent member (within the meaning of the German Corporate Governance Code).
Mr. Walt is not a member of other mandatory supervisory boards or comparable boards with supervisory function.